| Literature DB >> 23384348 |
Todd J Vento1, David W Cole, Katrin Mende, Tatjana P Calvano, Elizabeth A Rini, Charla C Tully, Wendy C Zera, Charles H Guymon, Xin Yu, Kristelle A Cheatle, Kevin S Akers, Miriam L Beckius, Michael L Landrum, Clinton K Murray.
Abstract
BACKGROUND: The US military has seen steady increases in multidrug-resistant (MDR) gram-negative bacteria (GNB) infections in casualties from Iraq and Afghanistan. This study evaluates the prevalence of MDR GNB colonization in US military personnel.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23384348 PMCID: PMC3610270 DOI: 10.1186/1471-2334-13-68
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Number of participants colonized with gram-negative bacteria by body site of 101non-deployed, healthy US military service members presenting to a troop medical clinic
| Total MDR bacteria (all | 0 | 0 | 0 | 0 | 0 | 0 | 2 (3) | 2 (3) |
| Total non-MDR bacteria | 4 (4) | 14 (17) | 11 (12) | 9 (14) | 7 (7) | 27 (35) | 65 (99) | 85 (188) |
| 0 | 1 (1) | 0 | 0 | 1 (1) | 4 (4) | 2 (2) | 8 (8) | |
| 0 | 1 (1) | 0 | 1 (1) | 0 | 4 (5) | 2 (2) | 8 (9) | |
| 0 | 1 (1) | 0 | 0 | 1 (1) | 2 (2) | 1 (1) | 5 (5) | |
| 0 | 0 | 0 | 0 | 0 | 0 | 11 (11) | 11 (11) | |
| 1 (1) | 0 | 2 (2) | 1 (1) | 0 | 0 | 1 (1) | 5 (5) | |
| 0 | 1 (1) | 0 | 0 | 1 (1) | 0 | 4 (4) | 6 (6) | |
| 2 (2) | 0 | 2 (3) | 1 (1) | 0 | 0 | 49 (54) | 49 (60) | |
| 0 | 1 (1) | 0 | 1 (1) | 0 | 0 | 2 (3) | 2 (5) | |
| 0 | 1 (1) | 1 (1) | 2 (2) | 0 | 1 (1) | 8 (8) | 12 (13) | |
| 0 | 0 | 1 (1) | 0 | 0 | 1 (1) | 0 | 2 (2) | |
| 0 | 4 (4) | 0 | 0 | 0 | 2 (2) | 0 | 5 (6) | |
| 1 (1) | 1 (1) | 4 (4) | 1 (1) | 2 (2) | 2 (2) | 1 (1) | 9 (12) | |
| 0 | 2 (2) | 0 | 0 | 0 | 3 (3) | 1 (1) | 5 (6) | |
| Other*** | 0 | 4 (4) | 1 (1) | 4 (7) | 2 (2) | 12 (15) | 11 (11) | 34 (40) |
Number of isolates in parentheses.
*100 participants were swabbed at the oropharynx and 99 individuals were swabbed in the perirectal sites.
**Participants can be colonized with multiple bacteria or clones of bacteria.
***Other isolates include: Acinetobacter species (2), Acinetobacter haemolyticus (2), Burkholderia cepacia, Burkholderia gladioli, Comamonas testosteroni, Enterobacter hormaechei, Leclericia adecarboxylata, Moraxella species (6), Morganella morganii (3), Ochrobactrum anthropi (2), Pantoea agglomerans (6), Providencia alcalifaciens, Pseudomonas species, Pseudomonas fluorescens, Pseudomonas luteola, Pseudomonas oryzihabitans (3), Pseudomonas putida, Pseudomonas stutzeri (2), Rhizobium radiobacter, Shewanella putrefaciens, Shigella flexneri (2).
Comparison of participants* from the US and Afghanistan study sites with gram-negative bacteria
| Age (median, IQR) | 22 (20,25) | 23 (22,25.8) | 0.07 |
| Gender- males | 69 | 100 | <0.01 |
| Total colonized | 85 | 84 | 0.98 |
| Nares | 4 | 12 | 0.04 |
| Oropharynx | 14 | 8 | 0.26 |
| Axilla | 11 | 13 | 0.65 |
| Groin | 9 | 23 | <0.01 |
| Hand | 7 | 12 | 0.22 |
| Foot | 27 | 13 | 0.15 |
| Perirectal | 66 | 70 | 0.48 |
| Total multidrug resistant (MDR) colonized | 2 | 11 | 0.01 |
| Groin | 0 | 4 | 0.12 |
| Foot | 0 | 1 | 0.50 |
| Perirectal | 2 | 9 | 0.03 |
| All bacteria | | | |
| | 8 | 4 | 0.24 |
| | 8 | 13 | 0.24 |
| | 11 | 5 | 0.19 |
| | 5 | 9 | 0.28 |
| | 6 | 3 | 0.50 |
| | 51 | 67 | 0.02 |
| | 12 | 20 | 0.12 |
| | 5 | 2 | 0.45 |
| | 9 | 1 | 0.02 |
| | 5 | 0 | 0.06 |
| Total sites colonized | | | 0.44 |
| 0 | 16 | 16 | |
| 1 | 48 | 36 | |
| 2 | 24 | 31 | |
| 3 | 10 | 15 | |
| 4 | 3 | 2 | |
| Total gram-negative rod bacteria isolates | | 0.62 | |
| 0 | 16 | 16 | |
| 1 | 32 | 24 | |
| 2 | 23 | 22 | |
| 3 | 17 | 21 | |
| 4 | 7 | 10 | |
| 5 | 4 | 5 | |
| 6 | 0 | 1 | |
| 7 | 2 | 0 | |
| 10 | 0 | 1 | |
*Participants can be colonized with multiple bacteria or clones of bacteria.
Figure 1Pulsed-field gel electrophoresis pattern, country of study, and body region of ESBL-producing and multidrug-resistant (MDR) along with TEM and CTX-M mechanisms of resistance
Antimicrobial resistance of multidrug-resistant
| | | | |||||||||||||||||||
| 6 | US | MDR | S | R | R | S | R | R | R | R | R | S | R | S | R | S | R | S | R | I | R |
| 6 | US | MDR | S | R | R | S | R | R | R | R | R | S | R | S | R | S | R | S | R | I | R |
| 9 | US | ESBL | S | R | R | R | I | R | R | R | R | S | S | S | R | S | R | S | S | S | R |
| % susceptible by unique isolate per unique participant | 100 | 0 | 0 | 50 | 0 | 0 | 0 | 0 | 0 | 100 | 50 | 100 | 0 | 100 | 0 | 100 | 50 | 50 | 0 | ||
| 1 | Afghan | MDR | S | R | R | S | R | R | R | R | S | S | S | S | S | S | S | S | I | S | R |
| 1 | Afghan | MDR | S | R | R | S | R | R | R | R | S | S | S | S | S | S | S | S | I | S | R |
| 2 | Afghan | ESBL | S | R | R | R | I | R | R | R | R | S | R | S | R | S | R | S | S | R | R |
| 3 | Afghan | ESBL | S | R | R | R | S | R | R | R | S | S | S | S | S | S | S | S | S | S | R |
| 3 | Afghan | ESBL | S | R | R | R | S | R | R | R | S | S | S | S | S | S | S | S | I | S | R |
| 4 | Afghan | ESBL | S | R | R | R | I | R | R | R | S | S | S | S | S | S | S | S | S | S | S |
| 5 (PFT 5) | Afghan | ESBL | S | R | R | R | S | R | R | R | S | S | S | S | S | S | S | S | S | S | R |
| 5 (PFT 8) | Afghan | ESBL | S | R | R | R | S | R | R | R | R | S | S | S | R | S | R | S | S | R | R |
| 7 | Afghan | ESBL | S | R | R | R | S | R | R | R | R | S | S | S | R | S | R | I | S | S | R |
| 8 | Afghan | ESBL | S | R | R | R | S | R | R | R | R | S | S | S | R | S | R | S | S | R | R |
| 10 | Afghan | ESBL | S | R | R | R | S | R | R | R | S | S | S | S | S | S | S | I | S | S | R |
| 11 | Afghan | ESBL | S | R | R | R | S | R | R | R | R | S | S | S | R | S | R | S | S | S | R |
| 12 | Afghan | ESBL | S | R | R | R | S | R | R | R | S | S | S | S | S | S | I | S | S | S | R |
| 12 | Afghan | ESBL | S | R | R | R | S | R | R | R | S | S | S | S | S | S | I | S | S | S | R |
| 13 | Afghan | ESBL | S | R | R | R | S | R | R | R | R | S | S | S | R | S | R | S | S | R | R |
| % susceptible by unique isolate per unique participant | 100 | 0 | 0 | 8 | 75 | 0 | 0 | 0 | 42 | 100 | 92 | 100 | 50 | 100 | 42 | 83 | 92 | 75 | 8 | ||
MDR- multidrug-resistant; ESBL- Extended spectrum beta-lactamase producing; PFT- pulsed-field type; S-Susceptible; R-Resistant; I-Intermediate.
Doxycycline, minocycline and tetracycline resistance and tetracycline resistance genes for multidrug-resistant isolates
| 1 | + | - | R | S | R |
| 1 | + | - | R | S | R |
| 2 | - | + | R | R | R |
| 3 | + | - | I | S | R |
| 3 | + | - | I | S | R |
| 4 | - | - | S | S | S |
| 5 (PFT 5) | - | + | R | I | R |
| 5 (PFT 8) | + | - | R | I | R |
| 6 | + | - | R | I | R |
| 6 | + | - | R | I | R |
| 7 | - | + | R | R | R |
| 8 | + | - | R | I | R |
| 9 | - | + | R | R | R |
| 10 | - | + | R | R | R |
| 11 | - | + | R | R | R |
| 12 | + | - | R | I | R |
| 12 | + | - | R | I | R |
| 13 | + | - | R | I | R |
- no gene detected; + gene detected; R- resistant, I- intermediate, S-susceptible; PFT- pulsed-field type.
Number of participants with gram-negative bacteria by body site of 100 healthy US military service members deployed to Afghanistan who presented to an acute care clinic
| Total MDR bacteria (all | 0 | 0 | 0 | 4 (4) | 0 | 1 (1) | 9 (10) | 11 (15) |
| Total non-MDR bacteria | 12 (13) | 8 (10) | 13 (14) | 20 (27) | 12 (12) | 12 (14) | 65 (107) | 80 (197) |
| 0 | 0 | 0 | 0 | 1 (1) | 3 (3) | 0 | 4 (4) | |
| 0 | 0 | 3 (3) | 2 (2) | 5 (5) | 5 (5) | 1 (1) | 13 (16) | |
| 0 | 1 (1) | 0 | 2 (2) | 1 (1) | 2 (2) | 1 (1) | 5 (7) | |
| 1 (1) | 0 | 0 | 0 | 0 | 1 (1) | 3 (3) | 5 (5) | |
| 5 (6) | 2 (2) | 4 (4) | 1 (1) | 1 (1) | 0 | 2 (2) | 9 (16) | |
| 0 | 1 (2) | 0 | 1 (1) | 0 | 1 (1) | 0 | 3 (4) | |
| 2 (2) | 0 | 3 (3) | 12 (17) | 0 | 0 | 57 (75) | 59 (97) | |
| 3 (3) | 0 | 0 | 0 | 0 | 0 | 0 | 3 (3) | |
| 0 | 0 | 2 (2) | 2 (2) | 0 | 0 | 19 (20) | 20 (24) | |
| 0 | 0 | 1 (1) | 0 | 0 | 0 | 2 (2) | 3 (3) | |
| 0 | 1 (1) | 0 | 1 (1) | 0 | 0 | 2 (2) | 2 (4) | |
| 1 (1) | 1 (2) | 0 | 0 | 0 | 0 | 0 | 1 (3) | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other** | 0 | 2 (2) | 1 (1) | 1 (1) | 4 (4) | 2 (2) | 1 (1) | 11 (11) |
Number of isolates in ().
* Participants can be colonized with multiple bacteria or clones of bacteria.
**Other isolates includes: Comamonas testosteroni, Enterobacter gergoviae, Moraxella species (2), Pantoea agglomerans (3), Pseudomonas species, Pseudomonas putida, Serratia liquefaciens, Sphingomonas paucimobilis.